CGTLive’s Weekly Rewind – June 9, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Legend Biotech Seeks Expanded Use for Cilta-cel in Lenalidoimide-Refractory Multiple Myeloma

The most recent data from CARTITUDE-4 were presented at the 2023 ASCO Meeting.

2. Nausheen Ahmed, MD, on Real-world Efficacy Data for Brexu-cel in Patients With R/R Mantle Cell Lymphoma

The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.

3. TCR-T Therapy Shows Antitumor Activity in HBV-Hepatocellular Carcinoma

Updated data were presented at the ISCT 2023 Meeting.

4. Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

The associate professor at Medical College of Wisconsin discussed the rationale for the CARTITUDE-4 study and its latest updates.

5. BrainStorm Cell Therapeutics Gets AdComm and PDUFA Dates for ALS Cell Therapy NurOwn

The FDA’s Advisory Committee meeting is scheduled for September 27, 2023, and the PDUFA date for the company’s BLA review is set for December 8, 2023.